GLP-3 RT Injection Pen 30mg – Adjustable dosage

GLP-3 RT is a triple incretin receptor agonist simultaneously targeting glucagon like peptide 1 (GLP-1), glucose dependent insulinotropic polypeptide (GIP), and glucagon receptors. The most advanced incretin based research compound in CSD’s metabolic peptide range. Hudson Science’s 30mg adjustable dose pen delivers this triple receptor agonist with three selectable dose increments: 2.5mg, 5mg, and 10mg per administration, providing a level of titration precision within a single pen device that fixed dose and standard adjustable pen formats do not offer, allowing researchers to select between three defined dose points across the protocol timeline without reconstitution preparation.

The three selectable dose increments are a meaningful research design advantage for triple incretin agonist protocols. The 2.5mg setting supports the lowest concentration administration point suited to initial receptor response characterization and conservative dose initiation. The 5mg setting provides the mid range option for established maintenance phase protocols. The 10mg setting delivers the highest per administration dose from this pen. Suited to elevated dose response evaluation within the pen’s 30mg total supply, providing three full administrations at the maximum setting before exhaustion. This defined three point dose selection within a single device supports structured dose escalation research designs without requiring separate vials or pen units for each concentration point.

CSD’s GLP-3 RTA range spans the most comprehensive incretin agonist format selection in our catalogue: lyophilized vials from 10mg through 60mg across Hudson Science and iLab Pharma, the Hudson Science 10mg 5 pack, adjustable dose pens at 16mg and 40mg from F40 Biotech, and this Hudson Science 30mg three setting selectable dose pen. The triple receptor mechanism remains consistent across all presentations. GLP-1 receptor activation driving glucose dependent insulin secretion and satiety signaling, GIP receptor activation contributing complementary insulinotropic and adipose tissue metabolic effects, and glucagon receptor co activation adding hepatic glucose regulation, thermogenic energy expenditure, and lipolytic activity.

Hudson Science formulations are stocked by Canada Steroid Depot following the same rigorous third party lab verification process applied to every product in our range. Each batch is tested for concentration accuracy and purity before being made available, with COA documentation available on request. CSD’s sourcing standards apply uniformly across all manufacturers we carry, and Hudson Science’s GLP-3 RT pen meets those standards consistently. All orders ship discreetly across Canada in plain, unmarked packaging with no identifying information on the exterior.

Store at 2–8°C away from direct light. Do not freeze. Keep upright. Intended for research purposes only.

Commonly researched alongside dual incretin agonist compounds and Semaglutide in comparative receptor pathway and metabolic activity studies. Browse CSD’s full peptide range for complete sourcing.